Cargando…
Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing
The purpose of this review is to explore how metabolomics can help uncover new biomarkers and mechanisms for cardiovascular ageing. Cardiovascular ageing refers to cardiovascular structural and functional alterations that occur with chronological ageing and that can lead to the development of cardio...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120371/ https://www.ncbi.nlm.nih.gov/pubmed/33783981 http://dx.doi.org/10.1002/ehf2.13274 |
_version_ | 1783692073676832768 |
---|---|
author | Koh, Angela S. Kovalik, Jean‐Paul |
author_facet | Koh, Angela S. Kovalik, Jean‐Paul |
author_sort | Koh, Angela S. |
collection | PubMed |
description | The purpose of this review is to explore how metabolomics can help uncover new biomarkers and mechanisms for cardiovascular ageing. Cardiovascular ageing refers to cardiovascular structural and functional alterations that occur with chronological ageing and that can lead to the development of cardiovascular disease. These alterations, which were previously only detectable on tissue histology or corroborated on blood samples, are now detectable with modern imaging techniques. Despite the emergence of powerful new imaging tools, clinical investigation into cardiovascular ageing is challenging because ageing is a life course phenomenon involving known and unknown risk factors that play out in a dynamic fashion. Metabolomic profiling measures large numbers of metabolites with diverse chemical properties. Metabolomics has the potential to capture changes in biochemistry brought about by pathophysiologic processes as well as by normal ageing. When combined with non‐invasive cardiovascular imaging tools, metabolomics can be used to understand pathological consequences of cardiovascular ageing. This review will summarize previous metabolomics and imaging studies in cardiovascular ageing. These methods may be a clinically relevant and novel approach to identify mechanisms of cardiovascular ageing and formulate or personalize treatment strategies. |
format | Online Article Text |
id | pubmed-8120371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81203712021-05-21 Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing Koh, Angela S. Kovalik, Jean‐Paul ESC Heart Fail Review The purpose of this review is to explore how metabolomics can help uncover new biomarkers and mechanisms for cardiovascular ageing. Cardiovascular ageing refers to cardiovascular structural and functional alterations that occur with chronological ageing and that can lead to the development of cardiovascular disease. These alterations, which were previously only detectable on tissue histology or corroborated on blood samples, are now detectable with modern imaging techniques. Despite the emergence of powerful new imaging tools, clinical investigation into cardiovascular ageing is challenging because ageing is a life course phenomenon involving known and unknown risk factors that play out in a dynamic fashion. Metabolomic profiling measures large numbers of metabolites with diverse chemical properties. Metabolomics has the potential to capture changes in biochemistry brought about by pathophysiologic processes as well as by normal ageing. When combined with non‐invasive cardiovascular imaging tools, metabolomics can be used to understand pathological consequences of cardiovascular ageing. This review will summarize previous metabolomics and imaging studies in cardiovascular ageing. These methods may be a clinically relevant and novel approach to identify mechanisms of cardiovascular ageing and formulate or personalize treatment strategies. John Wiley and Sons Inc. 2021-03-30 /pmc/articles/PMC8120371/ /pubmed/33783981 http://dx.doi.org/10.1002/ehf2.13274 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Koh, Angela S. Kovalik, Jean‐Paul Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
title | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
title_full | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
title_fullStr | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
title_full_unstemmed | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
title_short | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
title_sort | metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120371/ https://www.ncbi.nlm.nih.gov/pubmed/33783981 http://dx.doi.org/10.1002/ehf2.13274 |
work_keys_str_mv | AT kohangelas metabolomicsandcardiovascularimagingacombinedapproachforcardiovascularageing AT kovalikjeanpaul metabolomicsandcardiovascularimagingacombinedapproachforcardiovascularageing |